This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer. Studying samples collected from patients in the laboratory may help doctors learn more about the human papillomavirus and how often anal cancer occurs in patients with cervix, vagina, or vulvar cancer.
PRIMARY OBJECTIVES: I. To estimate the prevalence of invasive squamous cell carcinoma of the anus in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. SECONDARY OBJECTIVES: I. To estimate the prevalence of anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. EXPLORATORY OBJECTIVES: I. To estimate the clinical performance (sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios) of anal pap testing to diagnose anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. II. To estimate the clinical performance (sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios) of anal high-risk human papillomavirus (HPV) testing to diagnose anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. III. To estimate the clinical performance (sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios) of anal pap testing and HPV testing (anal "cotesting") to diagnose anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. IV. To determine associations between gut and cervical microbiomes and anal dysplasia/carcinoma in women with high-grade dysplasia or carcinoma of the cervix, vagina, or vulva. V. To estimate the prevalence of oral HPV infection in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. VI. To compare a new HPV point of care test developed by Rice University with current standard HPV testing. OUTLINE: Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
409
Undergo anal, cervical, vaginal, and oral sample collection
Correlative studies
Lyndon Baines Johnson General Hospital
Houston, Texas, United States
M D Anderson Cancer Center
Houston, Texas, United States
Prevalence of invasive squamous cell carcinoma of the anus
Will estimate the prevalence of invasive squamous cell carcinoma of the anus in women with 95% confidence intervals.
Time frame: Up to 5 years
Sensitivity and specificity of anal pap testing to diagnose anal dysplasia
Will use the results of anoscopy as the true state of the patient and will estimate with 95% confidence intervals.
Time frame: Up to 5 years
Sensitivity and specificity of anal human papillomavirus (HPV) testing to diagnose anal dysplasia
Will use the results of anoscopy as the true state of the patient and will estimate with 95% confidence intervals.
Time frame: Up to 5 years
Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia
Will use the results of anoscopy as the true state of the patient and will estimate with 95% confidence intervals.
Time frame: Up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.